Fig. 2

The prognostic value of MCM6 in three validated clinical neuroblastoma datasets and the value of tumor INSS staging and risk classification. (A-B) Kaplan-Meier analysis of OS and EFS based on the MCM6 expression in Kocak dataset, and the log-rank test P value is displayed (n = 476, 173 patients without survival information were not included in the analysis); (C-D) Kaplan-Meier analysis of OS and EFS based on the MCM6 expression in SEQC dataset, and the log-rank test P value is displayed (n = 498); (E-F) Kaplan-Meier analysis of OS and EFS based on the MCM6 expression in Oberthuer dataset, and the log-rank test P value is displayed (n = 251); (G-I) The box plot shows the expression level of MCM6 in the above three public datasets in different INSS stages (stage 1, 2, 3, 4, 4 s); (J) The box plot shows the expression level of MCM6 in the high-risk group and low-risk group of neuroblastoma in the SEQC data set. Since the risk classification data were not included in the Kocak and Oberthuer datasets, no relevant analysis was performed. The value is displayed as the mean ± SEM and statistical significance is expressed as* p < 0.05, *** p < 0.001